I am not sure if this is helpful
In settings with low background prevalence of tuberculosis (TB) infection, interferon-gamma release assays (IGRA) could be useful for diagnosing active TB. This study aims to evaluate the performance of QuantiFERON(R)-TB Gold (QFT-G) in the investigation for suspected active TB, with particular attention to patients originating in high-incidence countries.
Furthermore, factors associated with QFT-G results in patients with active TB were assessed.
Methods: From patients investigated for clinically suspected active TB, blood was obtained for QFT-G testing, in addition to routine investigations. Positive (PPV) and negative (NPV) predictive values for QFT-G were calculated, comparing patients with confirmed TB and those with other final diagnoses.
QFT-G results in TB patients originating from countries with intermediate or high TB incidence were compared with QFT-G results from a control group of recently arrived asymptomatic immigrants from high-incidence countries. Factors associated with QFT-G outcome in patients with confirmed TB were assessed.
Results: Among 141 patients, 41/70 (58.6%) with confirmed TB had a positive QFT-G test, compared to 16/71 (22.6%) patients with other final diagnoses, resulting in overall PPV of 71.9% and NPV of 67.6%.
For patients with pulmonary disease, PPV and NPV were 61.1% and 67.7%, respectively, and 90.5% and 66.7% for subjects with extrapulmonary manifestations. Comparing patients from high-incidence countries with controls yielded a PPV for active TB of 76.7%, and a NPV of 82.7%.
Patients with confirmed TB and positive QFT-G results were characterized by a lower median peripheral white blood cell count (5.9E9/L vs. 8.8E9/L; P<.001) and a higher median body mass index (22.7 vs.
20.7; P=0.043) as compared to QFT-G-negative TB patients.
Conclusions: The overall PPV and NPV of QFT-G for identifying active TB were unsatisfactory, especially for pulmonary disease. Thus, the usefulness of QFT-G for this purpose is questionable.
However, a high PPV was observed for extrapulmonary TB and QFT-G might be considered in the diagnostic process in this situation. The PPV and NPV for identifying active TB among persons originating from regions with high-and intermediate TB incidence was similar to that observed in subjects originating in the low-incidence region.
Author: Niclas WinqvistPer BjorkmanAnn NorenHakan Miorner
Credits/Source: BMC Infectious Diseases 2009, 9:105
- Forums
- ASX - By Stock
- CST
- mycrolab tb testing
CST
castile resources ltd
Add to My Watchlist
0.00%
!
5.6¢

mycrolab tb testing, page-8
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
5.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $17.12M |
Open | High | Low | Value | Volume |
5.9¢ | 5.9¢ | 5.4¢ | $76.73K | 1.378M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | 5.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.6¢ | 636 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | 0.054 |
3 | 276416 | 0.053 |
2 | 58843 | 0.051 |
2 | 70019 | 0.050 |
1 | 38173 | 0.048 |
Price($) | Vol. | No. |
---|---|---|
0.056 | 636 | 1 |
0.060 | 40000 | 1 |
0.061 | 18711 | 1 |
0.067 | 200000 | 1 |
0.069 | 17154 | 1 |
Last trade - 15.54pm 27/06/2025 (20 minute delay) ? |
Featured News
CST (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online